101,471 results match your criteria Lung Cancer Non-Small Cell


Feasibility and clinical utility of a workflow interfacing radiation oncology lung stereotactic body radiotherapy treatment planning and diagnostic radiology.

Pract Radiat Oncol 2022 Jun 22. Epub 2022 Jun 22.

Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah. Electronic address:

Stereotactic body radiotherapy (SBRT) is commonly used to treat early stage non-small cell lung cancer (NSCLC). SBRT beam arrangements include multiple entry/exit pathways resulting in irregular low dose distributions within normal lung parenchyma. An improved understanding of post-treatment radiographic changes may improve the ability to predict clinical complications including radiation pneumonitis as well as assist in early detection of local failures. Read More

View Article and Full-Text PDF

Association of Lymph Node Sampling and Clinical Volume in Lobectomy for Non-Small Cell Lung Cancer.

Ann Thorac Surg 2022 Jun 22. Epub 2022 Jun 22.

Division of Thoracic Surgery, Massachusetts General Hospital, Boston MA.

Background: Sampling ≥10 lymph nodes during lobectomy for non-small cell lung cancer (NSCLC) is a current surveillance metric and potential quality metric of American College of Surgeons Commission on Cancer. We sought to determine guideline adherence and its relationship to hospital lobectomy volume within the Society of Thoracic Surgeons General Thoracic Surgery Database (STS-GTSD).

Methods: Participant-centers providing elective lobectomy for NSCLC within the STS-GTSD (2012-2019) were divided into tertiles according to annual volume. Read More

View Article and Full-Text PDF

A predictive model based on liquid biopsy for non-small cell lung cancer to assess patient's prognosis: Development and application.

Tissue Cell 2022 Jun 14;77:101854. Epub 2022 Jun 14.

Department of Respiratory, Hwa Mei Hospital, University of Chinese Academy of Sciences, China; Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, China.

Background And Objective: Improving ability to predict the prognosis of patients with progressive lung cancer is an important task in the era of precision medicine. Here, a predictive model based on liquid biopsy for non-small cell lung cancer (NSCLC) was established to improve prognosis prediction in patients with progressive NSCLC.

Methods: Clinical data and blood samples of 500 eligible patients were collected and screened from the electronic case database and blood sample center of Hwa Mei Hospital, University of Chinese Academy of Sciences and Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences. Read More

View Article and Full-Text PDF

Expression of Mir-489-3p as an Effective Marker of Poor Prognosis in Patients with Non-small-cell Lung Carcinoma.

Altern Ther Health Med 2022 Jun 24. Epub 2022 Jun 24.

Context: Lung carcinoma accounts for the majority of cancer deaths, and its 5-year survival rate isn't optimistic. Remarkable progress has been made in recent decades toward understanding the biological behavior of non-small-cell lung carcinoma (NSCLC) and creating targeted molecular therapies for diagnosis and treatment. However, little literature is available on the topic, and the clinical significance and application of miR-489-3p for NSCLC can't yet be determined. Read More

View Article and Full-Text PDF

Pralsetinib treatment for multiple fusions in lung adenocarcinoma: a case report.

J Int Med Res 2022 Jun;50(6):3000605221105368

Department of Oncology, The Affiliated Jiangyin Hospital of Southeast University Medical College, Wuxi, China.

Despite recent advances in treatments and knowledge of biomarkers, patients with metastatic lung cancer have a 5-year survival rate of 5%. Rearranged during transfection () fusions occur in 1% to 2% of lung cancer patients. Pralsetinib has been used to treat non-small cell lung cancer with a single fusion; however, there have been no reports regarding its use in patients with multiple fusions. Read More

View Article and Full-Text PDF

Prognostic factors for advanced lung cancer patients with do-not-intubate order in intensive care unit: a retrospective study.

BMC Pulm Med 2022 Jun 24;22(1):245. Epub 2022 Jun 24.

Department of Chest Medicine, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei, 112, Taiwan.

Background: The survival of patients with lung cancer undergoing critical care has improved. An increasing number of patients with lung cancer have signed a predefined do-not-intubate (DNI) order before admission to the intensive care unit (ICU). These patients may still be transferred to the ICU and even receive non-invasive ventilation (NIV) support. Read More

View Article and Full-Text PDF

Clinical significance of cyclin-dependent kinase inhibitor 2C expression in cancers: from small cell lung carcinoma to pan-cancers.

BMC Pulm Med 2022 Jun 24;22(1):246. Epub 2022 Jun 24.

Ward of Pulmonary and Critical Care Medicine, Department of Respiratory Medicine, The First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Nanning, 530021, Guangxi Zhuang Autonomous Region, People's Republic of China.

Background: Cyclin-dependent kinase inhibitor 2C (CDKN2C) was identified to participate in the occurrence and development of multiple cancers; however, its roles in small cell lung carcinoma (SCLC) remain unclear.

Methods: Differential expression analysis of CDKN2C between SCLC and non-SCLC were performed based on 937 samples from multiple centers. The prognosis effects of CDKN2C in patients with SCLC were detected using both Kaplan-Meier curves and log-rank tests. Read More

View Article and Full-Text PDF

Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients.

J Cancer Res Clin Oncol 2022 Jun 24. Epub 2022 Jun 24.

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Via Giuseppe Massarenti, 9, 40138, Bologna, Italy.

Purpose: The presence of bone metastasis at baseline has been associated with dismal prognosis under immunotherapy in advanced non-small cell lung cancer (NSCLC). Response Evaluation Criteria in Solid Tumors (RECIST) criteria may be limited for bone-specific response evaluation. Whether their assessment through MD Anderson (MDA) criteria predict immunotherapy efficacy is unknown. Read More

View Article and Full-Text PDF

Circ-HSP90A expedites cell growth, stemness, and immune evasion in non-small cell lung cancer by regulating STAT3 signaling and PD-1/PD-L1 checkpoint.

Cancer Immunol Immunother 2022 Jun 24. Epub 2022 Jun 24.

Department of Thoracic Surgery, The Second Affiliated Hospital of Air Force Medical University, No.569 Xinsi Road, Xi'an, 710038, Shaanxi, China.

Background: Circular RNAs (circRNAs) are important participators in tumor progression for their stable structure and high tissue-specific expression. The purpose of this research was to clarify the potential and mechanism of a novel circRNA-circ-HSP90A in non-small cell lung cancer (NSCLC).

Methods: Biological potentials of circ-HSP90A in NSCLC were measured by functional assays. Read More

View Article and Full-Text PDF

Local Control With Single-Fraction Lung Stereotactic Body Radiotherapy is not influenced by Non-Small Cell Lung Cancer Histologic Subtype.

Clin Lung Cancer 2022 Jun 3. Epub 2022 Jun 3.

Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.

Introduction/background: For early stage medically inoperable lung cancer treated with fractionated stereotactic body radiotherapy (SBRT), higher local failure is associated with squamous carcinoma (SqC) compared to adenocarcinoma (AC). This study explored whether histology influences single-fraction SBRT local control.

Materials And Methods: We surveyed our prospective data registry from 12/2009 to 12/2019 for SF-SBRT cases with biopsy-proven AC or SqC only. Read More

View Article and Full-Text PDF

Influence of concomitant gastric acid suppressants use on the survival of patients with non-small cell lung cancer treated with programmed death-1/ligand-1 inhibitors: A meta-analysis.

Int Immunopharmacol 2022 Jun 21;110:108955. Epub 2022 Jun 21.

Department of Oncology, the First Affiliated Hospital of Bengbu Medical College, Bengbu 233000, China. Electronic address:

Introduction: Influence of concomitant use of gastric acid suppressants (GAS) on survival of non-small cell lung cancer (NSCLC) patients receiving programmed death-1/ligand-1 (PD-1/PD-L1) inhibitors has rarely been comprehensively evaluated. A meta-analysis was performed to systematically evaluate the effect of concomitant GAS in NSCLC patients receiving PD-1/PD-L1inhibitors.

Methods: Relevant observational studies were identified by search of Medline, Embase, and Web of Science databases from inception to May 26, 2022. Read More

View Article and Full-Text PDF

Psychological states regarding adjuvant chemotherapy in patients with non-small cell lung cancer.

Cancer Treat Res Commun 2022 Jun 14;32:100591. Epub 2022 Jun 14.

Department of Surgical Oncology, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. Electronic address:

Background: Understanding the anxieties and emotions of patients with lung cancer before and after radical surgery is crucial in the decision to undergo postoperative adjuvant chemotherapy. However, the psychological states and changes associated with adjuvant chemotherapy during perioperative periods in patients with non-small cell lung cancer (NSCLC) remain unclear.

Patients And Methods: Participants with a self-reported diagnosis of pathological stage II or III NSCLC who underwent complete surgical resection and received information on postoperative adjuvant chemotherapy (n = 101) were sampled from an online panel in Japan from October 9 to November 19, 2020. Read More

View Article and Full-Text PDF

Applying Artificial Neural Networks to Develop a Decision Support Tool for Tis-4N0M0 Non-Small-Cell Lung Cancer Treated With Stereotactic Body Radiotherapy.

JCO Clin Cancer Inform 2022 Jun;6:e2100176

Department of Radiology, Keio University School of Medicine, Tokyo, Japan.

Purpose: Clear evidence indicating whether surgery or stereotactic body radiation therapy (SBRT) is best for non-small-cell lung cancer (NSCLC) is lacking. SBRT has many advantages. We used artificial neural networks (NNs) to predict treatment outcomes for patients with NSCLC receiving SBRT, aiming to aid in decision making. Read More

View Article and Full-Text PDF

Chaperonin containing TCP1 as a marker for identification of circulating tumor cells in blood.

PLoS One 2022 24;17(6):e0264651. Epub 2022 Jun 24.

Burnett School of Biomedical Science, College of Medicine, University of Central Florida, Orlando, Florida, United States of America.

Herein we report the use of Chaperonin-Containing TCP-1 (CCT or TRiC) as a marker to detect circulating tumor cells (CTCs) that are shed from tumors during oncogenesis. Most detection methods used in liquid biopsy approaches for enumeration of CTCs from blood, employ epithelial markers like cytokeratin (CK). However, such markers provide little information on the potential of these shed tumor cells, which are normally short-lived, to seed metastatic sites. Read More

View Article and Full-Text PDF

Cost-effectiveness analysis of durvalumab as a maintenance treatment for patients with locally advanced, unresectable, stage Ⅲ nsclc in china.

PLoS One 2022 24;17(6):e0270118. Epub 2022 Jun 24.

Shenyang Pharmaceutical University, Shenyang, China.

Objective: The aim of this study was to evaluate the cost-effectiveness of durvalumab compared with Best supportive care (BSC) after chemoradiotherapy in patients with stage III non-small cell lung cancer from healthcare system perspective in China.

Methods: A dynamic state transition model was adopted to simulate life time, direct medical costs and QALYs. In the base case scenario, for patients with unresectable, stage Ⅲ non-small cell lung cancer whose disease has not progressed after platinum-based chemoradiation therapy, the treatment group would use durvalumab whereas the control group would use BSC. Read More

View Article and Full-Text PDF

CircDLG1 promotes malignant development of non-small cell lung cancer through regulation of the miR-630/CENPF axis.

Strahlenther Onkol 2022 Jun 24. Epub 2022 Jun 24.

Department of Clinical Oncology, Shengjing Hospital of China Medical University, No. 39 Huaxiang Road, 110022, Tiexi District, Shenyang, Liaoning Province, China.

Background: Circular RNAs (circRNAs) have been reported to be crucial modulatory molecules in the etiology of non-small cell lung cancer (NSCLC). This study aimed to probe the precise role and mechanism of circRNA discs large MAGUK scaffold protein 1 (circDLG1) in the malignant progression of NSCLC.

Methods: The abundances of circDLG1, miR-630, and centromere protein F (CENPF) mRNAs were gauged by quantitative real-time polymerase chain reaction (qRT-PCR). Read More

View Article and Full-Text PDF

Intraoperative conversion from video-assisted thoracoscopic lobectomy to thoracotomy for non-small cell lung cancer: does it have an impact on long-term survival?

Interact Cardiovasc Thorac Surg 2022 Jun 24. Epub 2022 Jun 24.

Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, PR China.

A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed was whether intraoperative conversion to thoracotomy have an impact on long-term survival for patients with non-small cell lung cancer (NSCLC) who underwent video-assisted thoracoscopic lobectomy initially? A total of 461 papers were found using the reported search, of which 6 retrospective cohort studies represented the best evidence to answer the clinical question. The authors, date of publication, journal, country of the authors, patient group, study type, relevant outcomes, and results of these papers are tabulated. Read More

View Article and Full-Text PDF

Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer.

Cancer Res 2022 Jun 24. Epub 2022 Jun 24.

Stanford University, Stanford, CA, United States.

Genomic profiling of Bronchoalveolar Lavage (BAL) samples may be useful for tumor profiling and diagnosis in the clinic. Here, we compared tumor-derived mutations detected in BAL samples from subjects with non-small cell lung cancer (NSCLC) to those detected in matched plasma samples. CAncer Personalized Profiling by deep Sequencing (CAPP-Seq) was used to genotype DNA purified from BAL, plasma and tumor samples from patients with NSCLC. Read More

View Article and Full-Text PDF

Cost-effectiveness of ensartinib for patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer in China.

J Comp Eff Res 2022 Jun 24. Epub 2022 Jun 24.

College of Pharmacy, Anhui University of Chinese Medicine, Hefei, Anhui, 230000, China.

Crizotinib and ensartinib improved survival in patients with arrangement non-small-cell lung cancer (NSCLC); however, the economic outcomes of using ensartinib versus crizotinib are still unclear. The objective of this study was to assess the cost-effectiveness of ensartinib versus crizotinib for -positive NSCLC patients from the perspective of China's healthcare system. A partitioned survival model with three health states (stable, progressive and death) was developed. Read More

View Article and Full-Text PDF

Targeting molecular alterations in non-small-cell lung cancer: what's next?

Per Med 2022 Jun 24. Epub 2022 Jun 24.

Thoracic Tumors Unit, Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, 08036, Spain.

In recent years, major advances have been achieved in our understanding of non-small-cell lung cancer (NSCLC) with oncogenic driver alterations and in the specific treatment of these with tyrosine kinase inhibitors. Currently, state-of-the-art management of patients with NSCLC (particularly adenocarcinoma or non-adenocarcinoma but with mild tobacco exposure) consists of the determination of , ,  and status, as they have US FDA and EMA approved targeted therapies. The increase in molecular knowledge of NSCLC and the development of drugs against other targets has settled new therapeutic indications. Read More

View Article and Full-Text PDF

Overexpression of TRAF4 promotes lung cancer growth and EGFR-dependent phosphorylation of ERK5.

FEBS Open Bio 2022 Jun 23. Epub 2022 Jun 23.

Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.

Tumor necrosis factor receptor-associated factor 4 (TRAF4) is overexpressed in a variety of carcinomas of different origins, but its role in tumorigenesis remains incompletely understood. Previous studies suggest that TRAF4 promotes EGFR activation in non-small cell lung cancer (NSCLC). However, the downstream signaling pathway of TRAF4-mediated EGFR activation, as well as its effects on tumor cells, have not been fully elucidated. Read More

View Article and Full-Text PDF

Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency.

Cancer Med 2022 Jun 23. Epub 2022 Jun 23.

Upstate Cancer Center, Upstate Medical University, Syracuse, New York, USA.

Introduction: New treatment strategies for advanced non-small-cell lung carcinoma (NSCLC) include synthetic lethality targets focused on protein arginine methyl transferases such as PRMT5 that exploit the impact of genomic loss of methylthioadenosine phosphorylase (MTAP).

Methods: Twenty nine thousand three hundred seventy nine advanced NSCLC cases underwent hybrid-capture based comprehensive genomic profiling between June 1, 2018 and May 31, 2020. PD-L1 expression was determined by immunohistochemistry (Dako 22C3 PharmDx assay). Read More

View Article and Full-Text PDF

The role of the LINC01234/miR-433-3p/GRB2 ceRNA network in NSCLC cell malignant proliferation.

Comb Chem High Throughput Screen 2022 Jun 24. Epub 2022 Jun 24.

Department of Cardiothoracic Surgery , Jinling Hospital, zhongshan road 305, China.

Background: Non-small cell lung cancer (NSCLC) is associated with high morbidity and mortality. Dysregulation of lncRNAs leads to NSCLC progression.

Objective: This study aims to explore the regulatory mechanism of lncRNA LINC01234 in NSCLC. Read More

View Article and Full-Text PDF

Symptomatic Radiation Pneumonitis in NSCLC Patients Receiving EGFR-TKIs and Concurrent Once-daily Thoracic Radiotherapy: Predicting the Value of Clinical and Dose-volume Histogram Parameters.

Zhongguo Fei Ai Za Zhi 2022 Jun;25(6):409-419

Department of Thoracic Oncology and State Key Laboratory of Biotherapy, Cancer Center, 
West China Hospital, Sichuan University, Chengdu 610041, China.

Background: The incidence of symptomatic radiation pneumonitis (RP) and its relationship with dose-volume histogram (DVH) parameters in non-small cell lung cancer (NSCLC) patients receiving epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and concurrent once-daily thoracic radiotherapy (TRT) remain unclear. We aim to analyze the values of clinical factors and dose-volume histogram (DVH) parameters to predict the risk for symptomatic RP in these patients.

Methods: Between 2011 and 2019, we retrospectively analyzed and identified 85 patients who had received EGFR-TKIs and once-daily TRT simultaneously (EGFR-TKIs group) and 129 patients who had received concurrent chemoradiotherapy (CCRT group). Read More

View Article and Full-Text PDF

[Analysis of the Efficacy of Immunotherapy in Elderly Patients with Lung Cancer].

Zhongguo Fei Ai Za Zhi 2022 Jun;25(6):401-408

Department of Medical Oncology, Beijing Tuberculosis and Thoracic Tumor Research Institute, 
Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.

Background: Immunotherapy represented by immune checkpoint inhibitors (ICIs) has become the standard treatment for patients with non-oncogenic advanced non-small cell lung cancer (NSCLC). While lung cancer is most prevalent in elderly patients, these patients are rarely included in pivotal clinical trial studies. We aimed to describe the efficacy and safety of immunotherapy for elderly patients in the "real-world". Read More

View Article and Full-Text PDF

Continuous Vaginal Bleeding Induced By EGFR-TKI in Premenopausal Female Patients With EGFR Mutant NSCLC.

Front Oncol 2022 7;12:805538. Epub 2022 Jun 7.

Department of Thoracic Oncology of Cancer Center, West China Hospital, Sichuan University, Chengdu, China.

EGFR-TKI is widely used for EGFR-mutant NSCLC patients. Bleeding is reported as a neglected adverse effect induced by EGFR-TKI. Female patients with lung adenocarcinoma have a high frequency of EGFR mutations. Read More

View Article and Full-Text PDF

Pembrolizumab-induced aseptic meningitis in a patient with non-small cell lung cancer: A case report and literature review of aseptic meningitis as an immune-related adverse event.

Mol Clin Oncol 2022 Jul 1;17(1):120. Epub 2022 Jun 1.

Department of Multidisciplinary Internal Medicine, Division of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan.

Aseptic meningitis is a rare immune-related adverse event (irAE), which occurs during treatment with immune checkpoint inhibitors (ICIs). This condition has non-specific symptoms and exhibits no clear signs on magnetic resonance imaging (MRI). There are only a few reports of aseptic meningitis caused by pembrolizumab treatment for non-small cell lung cancer (NSCLC). Read More

View Article and Full-Text PDF

Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours.

EClinicalMedicine 2022 Jul 27;49:101430. Epub 2022 May 27.

Department of Internal Medicine, Division of Hematology/Oncology, Mayo Clinic Cancer Center, Phoenix, AZ, USA.

Background: PT-112, the first pyrophosphate-platinum conjugate, causes immunogenic cell death in experimental models, leading to recruitment of tumour-infiltrating lymphocytes. PT-112 also associates with bone (osteotropism), likely driven by its pyrophosphate moiety. This is the first-in-human study of PT-112 monotherapy, exploring its safety and efficacy in a patient population where standard of care therapies were exhausted and novel treatment options are needed. Read More

View Article and Full-Text PDF

Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50.

Ther Adv Med Oncol 2022 16;14:17588359221105024. Epub 2022 Jun 16.

Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA.

Background: For patients with advanced non-small-cell lung cancer (NSCLC) and high (⩾50%) programmed cell death-ligand 1 (PD-L1) expression, effective first-line immune-oncology monotherapies with significant survival benefits are approved, cemiplimab being the most recent. In a phase III trial, cemiplimab demonstrated significantly improved overall survival (OS) and progression-free survival (PFS) chemotherapy in patients with advanced NSCLC and PD-L1 ⩾50%. A systematic literature review and network meta-analysis (NMA) was conducted to identify/compare the efficacy/safety of cemiplimab pembrolizumab or other immune-oncology monotherapies from randomized-controlled trials (RCTs) published in November 2010-2020. Read More

View Article and Full-Text PDF